Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease

Author(s): Paul J. Gilligan.

Journal Name: Current Topics in Medicinal Chemistry

Volume 15 , Issue 10 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) have been linked to several familial and sporadic late-onset cases of Parkinson’s disease. The cumulative data for the effects of mutant forms of this enzyme on neuronal degradation and the pathophysiology of Parkinson’s disease create a compelling case for drug discovery based on inhibition of the mutant forms of LRRK2. This review focuses on structure-activity relationships for inhibitors of LRRK2 and the data supporting a potential role of these agents in treating Parkinson’s disease.

Keywords: Kinase inhibitors, Leucine-rich repeat kinase 2 (LRRK2), Parkinson’s disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [927 - 938]
Pages: 12
DOI: 10.2174/156802661510150328223655
Price: $58

Article Metrics

PDF: 45